Author: Turcu, Gabriela; Nedelcu, Roxana Ioana; Ion, Daniela Adriana; Brînzea, Alice; Cioplea, Mirela Daniela; Jilaveanu, Lucia Beatrice; Zurac, Sabina Andrada
Title: CEACAM1: Expression and Role in Melanocyte Transformation Cord-id: e3xofc5g Document date: 2016_8_24
ID: e3xofc5g
Snippet: Metastases represent the main cause of death in melanoma patients. Despite the current optimized targeted therapy or immune checkpoint inhibitors the treatment of metastatic melanoma is unsatisfactory. Because of the poor prognosis of advanced melanoma there is an urgent need to identify new biomarkers to differentiate melanoma cells from normal melanocytes, to stratify patients according to their risk, and to identify subgroups of patients that require close follow-up or more aggressive therapy
Document: Metastases represent the main cause of death in melanoma patients. Despite the current optimized targeted therapy or immune checkpoint inhibitors the treatment of metastatic melanoma is unsatisfactory. Because of the poor prognosis of advanced melanoma there is an urgent need to identify new biomarkers to differentiate melanoma cells from normal melanocytes, to stratify patients according to their risk, and to identify subgroups of patients that require close follow-up or more aggressive therapy. Furthermore, melanoma progression has been associated with the dysregulation of cell adhesion molecules. We have reviewed the literature and have discussed the important role of the expression of the carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) in the development of melanoma. Thus, novel insights into CEACAM1 may lead to promising strategies in melanoma treatment, in monitoring melanoma patients, in assessing the response to immunotherapy, and in completing the standard immunohistochemical panel used in melanoma examination.
Search related documents:
Co phrase search for related documents- active disease and adaptive innate: 1, 2, 3
- active disease and adhesion molecule: 1, 2
- active disease and lymph node: 1, 2, 3
- active disease patient and acute sars cov respiratory syndrome coronavirus: 1, 2
- acute sars cov respiratory syndrome coronavirus and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars cov respiratory syndrome coronavirus and adaptive innate immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute sars cov respiratory syndrome coronavirus and adhesion glycoprotein: 1
- acute sars cov respiratory syndrome coronavirus and adhesion molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute sars cov respiratory syndrome coronavirus and liver metastasis: 1
- acute sars cov respiratory syndrome coronavirus and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adaptive innate and adhesion molecule: 1, 2, 3, 4, 5
- adaptive innate and lymph node: 1, 2, 3, 4, 5, 6, 7, 8
- adaptive innate immune response and adhesion molecule: 1
- adhesion glycoprotein and long cytoplasmic tail: 1, 2
- adhesion glycoprotein and lymph node: 1
- adhesion molecule and long cytoplasmic tail: 1
- adhesion molecule and lymph node: 1, 2, 3, 4
- liver metastasis and lymph node: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date